title: Finite Element Analysis of Denosumab Treatment Effects on Vertebral Strength in Ovariectomized Cynomolgus Monkeys.
abstract: Finite element analysis has not yet been validated for measuring changes in whole-bone strength at the hip or spine in people after treatment with an osteoporosis agent. Toward that end, we assessed the ability of a clinically approved implementation of finite element analysis to correctly quantify treatment effects on vertebral strength, comparing against direct mechanical testing, in cynomolgus monkeys randomly assigned to one of three 16-month-long treatments: sham surgery with vehicle (Sham-Vehicle), ovariectomy with vehicle (OVX-Vehicle), or ovariectomy with denosumab (OVX-DMAb). After treatment, T12 vertebrae were retrieved, scanned with micro-CT, and mechanically tested to measure compressive strength. Blinded to the strength data and treatment codes, the micro-CT images were coarsened and homogenized to create continuum-type finite element models, without explicit porosity. With clinical translation in mind, these models were then analyzed for strength using the U.S. Food and Drug Administration (FDA)-cleared VirtuOst software application (O.N. Diagnostics, Berkeley, CA, USA), developed for analysis of human bones. We found that vertebral strength by finite element analysis was highly correlated (R(2)  = 0.97; n = 52) with mechanical testing, independent of treatment (p = 0.12). Further, the size of the treatment effect on strength (ratio of mean OVX-DMAb to mean OVX-Vehicle, as a percentage) was large and did not differ (p = 0.79) between mechanical testing (+57%; 95% CI [26%, 95%]) and finite element analysis (+51% [20%, 88%]). The micro-CT analysis revealed increases in cortical thickness (+45% [19%, 73%]) and trabecular bone volume fraction (+24% [8%, 42%]). These results show that a preestablished clinical finite element analysis implementation-developed for human bone and clinically validated in fracture-outcome studies-correctly quantified the observed treatment effects of denosumab on vertebral strength in cynomolgus monkeys. One implication is that the treatment effects in this study are well explained by the features contained within these finite element models, namely, the bone geometry and mass and the spatial distribution of bone mass. © 2016 American Society for Bone and Mineral Research.
authors.affiliation: O.N. Diagnostics LLC, Berkeley, CA, USA.
authors.forename: David C
authors.initials: DC
authors.lastname: Lee
authors.affiliation: Charles River Laboratories Inc., Montréal, QC, Canada.
authors.forename: Aurore
authors.initials: A
authors.lastname: Varela
authors.affiliation: Phylon Pharma Services, Newbury Park, CA, USA.
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Kostenuik
authors.affiliation: Amgen Inc., Thousand Oaks, CA, USA.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Ominsky
authors.affiliation: University of California, Berkeley, CA, USA.
authors.forename: Tony M
authors.initials: TM
authors.lastname: Keaveny
mesh_terms: D000818:Animals; D001696:Biomechanical Phenomena; D000071556:Cancellous Bone / Q000000981:diagnostic imaging / Q000187:drug effects / Q000502:physiology; D000071538:Cortical Bone / Q000000981:diagnostic imaging / Q000187:drug effects / Q000502:physiology; D000069448:Denosumab / Q000494:pharmacology*; D005260:Female; D020342:Finite Element Analysis; D008252:Macaca fascicularis; D010052:Ovariectomy; D011857:Radiographic Image Interpretation, Computer-Assisted; D013131:Spine / Q000000981:diagnostic imaging / Q000187:drug effects / Q000502:physiology*; D055114:X-Ray Microtomography
chemical_list: D000069448:Denosumab
keywords: ANTIRESORPTIVES; BIOMECHANICS; BONE STRENGTH; OSTEOPOROSIS; TREATMENT